Your session is about to expire
← Back to Search
Cabozantinib + Atezolizumab for Prostate Cancer
Study Summary
This trial is testing whether cabozantinib and atezolizumab can shrink tumors in patients with metastatic castrate-resistant prostate cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 2 trial • 13 Patients • NCT02315430Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer has spread, but I don't have pain or loss of function from it.I haven't had a live vaccine within 30 days before starting the study treatment.I have brain metastases or cranial epidural disease.I have not had a severe infection in the last 4 weeks.I require dialysis.I have had treatment for any painful cancer spots before joining.I haven't had cancer treatment in the last 4 weeks.I have had leptomeningeal disease.I do not have any other cancer that needs treatment.I am currently being treated for an infection.I haven't had major surgery in the last 4 weeks and don't expect to need one during the study.I agree to use a condom during sex while on the study.I have a history of lung scarring or inflammation not caused by infections.I can take care of myself and perform daily activities.I have a serious wound, ulcer, or bone fracture that isn't healing.I am currently taking blood thinners or platelet inhibitors.My cancer has spread above my lower abdomen but can't be measured by scans.I do not have hepatitis, HIV/AIDS, or tuberculosis.My condition worsened after treatment with a new hormone therapy.My platelet count is at least 100,000 without recent transfusions.I have had a solid organ or bone marrow transplant.My kidney function, measured by creatinine levels, is within the normal range.My cancer can be measured and is located above my lower back area.My testosterone levels are very low, meeting the castration criteria.I have recovered from side effects of previous cancer treatments.I do not have any severe, uncontrolled health problems.I have not had chemotherapy for advanced prostate cancer after hormone therapy failed.I have previously been treated with cabozantinib, CD137 agonists, or immune checkpoint inhibitors.I haven't taken any kinase inhibitor medication in the last 2 weeks.My prostate cancer is confirmed without being a small cell type.I am a man aged 18 or older.My cancer has spread and worsened despite hormone therapy.I have high calcium levels in my blood that are causing symptoms.I haven't taken any immune-boosting drugs in the last 4 weeks or 5 half-lives of the drug.My liver function is significantly impaired.I frequently need procedures to remove excess fluid from my chest or abdomen.I have untreated or symptomatic thyroid issues.I haven't had radiation for bone metastasis in the last 2 weeks or any radiation in the last 4 weeks.My liver function tests are within acceptable limits despite having liver metastases.I have a condition that prevents my body from absorbing nutrients properly.My white blood cell count is healthy without needing medication.I have a sample of my tumor available for testing.I understand and can follow the study's requirements.My cancer pain is not managed with current treatments.
- Group 1: Treatment (cabozantinib, atezolizumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What medical conditions is Cabozantinib S-malate typically employed to combat?
"Small cell lung cancer is typically treated with Cabozantinib S-malate, though it can also be utilized to help patients who have previously been exposed to anti-vegf treatments, or those that are diagnosed with a malignant neoplasm and deemed at high risk."
Is enrollment for this experiment still available to participants?
"Indeed, clinicaltrials.gov reports that this trial is actively recruiting participants. It was initially made available on March 11th 2022 and recently updated for the same date. The research team needs 33 individuals from a single location to take part in the study."
What sort of health hazards could be associated with Cabozantinib S-malate?
"Based on our evaluation at Power, Cabozantinib S-malate is given a score of 2 for safety. This is because it has been tested in Phase 2 trials and there is documentation supporting its safety but not yet any proof that the drug can effectively treat the condition."
Is this an inaugural clinical trial of its kind?
"As of now, 446 studies are active for Cabozantinib S-malate across 1911 cities and 75 countries. The initial trial involving this drug occurred in 2008 and was sponsored by Hoffmann-La Roche, recruiting 720 patients to complete its Phase 2 approval process. Subsequently, 135 trials have been finalized since then."
What is the current enrollment threshold for this clinical trial?
"Affirmative. The information hosted on clinicaltrials.gov implies that the trial is currently enrolling patients, which were first mentioned on March 11th 2022 and updated most recently in the same month. 33 participants are required for this study at 1 medical facility."
Share this study with friends
Copy Link
Messenger